Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Badajoz – page 9

115 clinical trials in Badajoz, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Badajoz at a glance
115
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

115 trials in Badajoz

Open in trial search

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Safety of Trastuzumab, Tucatinib, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Spanish Society Of Cardiology

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Sacituzumab Govitecan for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Resistant to Hormone and CDK4/6 Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Solti Group

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Badajoz

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer treatments, including studies for HER2-positive, triple-negative, and hormone receptor-positive variants. Additional research explores novel therapies for bladder cancer and prostate cancer.

  • Advanced breast cancer treatments
  • Bladder cancer immunotherapy
  • Pancreatic cancer interventions
  • Colon cancer management

Studies evaluate combination therapies and novel drug applications for improved patient outcomes.

02 Metabolic Disorders

Innovative research targeting Type 1 Diabetes and obesity management. Studies investigate new therapeutic approaches for weight management and glycemic control in patients with multiple metabolic conditions.

  • Diabetes management
  • Obesity treatment
  • Cardiovascular safety studies

Focus on developing integrated treatment approaches for complex metabolic conditions.

03 Autoimmune Conditions

Comprehensive research into systemic lupus erythematosus and psoriatic arthritis, evaluating new therapeutic agents and treatment approaches for chronic autoimmune conditions.

  • Lupus treatment innovations
  • Arthritis management
  • Sjögren's syndrome therapy

Trials aim to improve long-term disease management and patient quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.